Marksons Pharma PAT slips to Rs 46.28 in Q2FY22
News

Marksons Pharma PAT slips to Rs 46.28 in Q2FY22

Marksans Pharma has reported consolidated financial results for the period ended September 30, 2021

  • By IPP Bureau | November 10, 2021

Financial Results (Q2 FY2022) - QoQ Comparison

Marksons Pharma has reported a total income of Rs. 369.768 crore during the period ended September 30, 2021,  as compared to Rs. 354.846 crore during the period ended June 30, 2021.

It posted a net profit of Rs. 46.288 crore for the period ended September 30, 2021, as against a net profit of Rs. 62.60 crore for the period ended June 30, 2021.

Financial Results (Q2 FY2022) - YoY comparison

The company has reported a total income of Rs. 369.768 crore during the period ended September 30, 2021, as compared to Rs.360.137 crore during the period ended September 30, 2020.

It  posted net profit of Rs.46.288 crore for the period ended September 30, 2021, as against a net profit of Rs.50.734 crore for the period ended September 30, 2020.

Financial Results (Half Year Ended FY2022) - YoY Comparison

The company has reported a total income of Rs.724.615 crores during the 6 months ended September 30, 2021, as compared to Rs.691.471 crores during the 6 months ended September 30, 2020.

It has posted a net profit of Rs.108.891 crore for the 6 months ended September 30, 2021, as against a net profit of Rs.100.099 crore for the 6 months ended September 30, 2020.

Upcoming E-conference

Other Related stories

Startup

Digitization